PerkinElmer’s DELFIA® Xpress PlGF 1-2-3™ assay, used in the ground-breaking ASPRE study (Rolnik et al, 2017), is the most sensitive first trimester screening assay for pre-eclampsia to date. Screening with DELFIA® Xpress PlGF 1-2-3™ assay before 13+6 weeks of gestation in combination with other biophysical markers and established risk factors, high risk women that are likely to develop preterm pre-eclampsia later in their pregnancy can be identified.
Aid in Diagnosis of Pre-eclampsia in the 2nd and 3rd trimester
During second and third trimesters of pregnancy, the DELFIA® Xpress sFlt-1 kit can be used for predicting the onset of pre-eclampsia and to manage pre-eclampsia in combination with the PlGF 1-2-3™ assay as a ratio of concentrations and with other clinical factors.
In addition to DELFIA® Xpress, the PlGF 1-2-3™ assay is also available for PerkinElmer’s AutoDELFIA® and Victor2™ D platforms. PerkinElmer’s biochemistry assays and supporting instruments are complemented by essential items such as human serum controls to ensure the integrity of results. We also supply dedicated pre-eclampsia screening software for risk calculations. Together, these products constitute a complete solution for pre-eclampsia management.
Products may not be licensed in accordance with the laws in all countries, such as the United States. Please check with your local representative for availability.
The VICTOR2™ D fluorometer is designed for all PerkinElmer diagnostic and screening assays based on either time-resolved fluorescence or prompt fluorescence. VICTOR2 D includes MultiCalc software for assay evaluation and quality control.
AutoDELFIA® immunoassay system for prenatal screening is supported by the widest available range of prenatal analytes available on any platform. Reliable and easy to use AutoDELFIA instrument offers high quality results both for aneuploidy and pre-eclampsia risk assessment during pregnancy.